Treatment of adult metastatic soft-tissue sarcoma with doxorubicin/ifosfamide: Better hematologic tolerance by G-CSF?

Oncology Research and Treatment

Volumn 19, Issue 2, 1996, Pages 159-162

  Weh, H J ^a   Wit de, M ^a   Zornig, C ^a   Hossfeld, D K ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Doxorubicin ifosfamide; G CSF; Hematotoxicity; Metastatic soft tissue sarcoma

Indexed keywords

DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; METASTASIS; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA;

EID: 0030014610     PISSN: 22965270     EISSN: None     Source Type: Journal    
DOI: 10.1159/000218783     Document Type: Article

References (12)

1. Loehrer PJ, Sledge GW, Nicaise C, Usakewicz J, Hainsworth JD, Martelo OJ, Omura G, Braun TJ: Ifosfamide plus doxorubicin in metastatic adult sarcomas: A multi-institutional phase II trial. J Clin Oncol 1989:7:1655-1659.
2. Schütte J, Mouridsen HT, Stewart W, Santoro A, van Oosterom AT, Somers R, Blacklcdge G, Verweig J, Dombemowsky P, Thomas D, Sylvester R for the EORTC Soft Tissue and Bone Sarcoma Group: Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. Eur J Cancer 1990:25:558-561.
3. Steward WP, Verweig J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rovesse J, Tursz T, Tucni E, van Oosterom AT, Warwick J, Greifenberg B, Thomas D, van Glabbeke M: Granulocyte-macro-phage colony-stimulating factor allows safe escalation of dose intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993:11:15-21.
4. Weh HJ, Agarwal K, Zornig C, Schwarz R, Dietel M, Hossfeld DK: Treatment results in metastatic soft tissue sarcoma with a combination of doxorubicin and dacarbazine or doxorubicin and ifosfamide. Cancer Chemother Pharmacol 1993:31 (suppl 2): 189-193.
5. Edmonson JH, Ryan LM, Blum RH, Brooks JSJ, Shiraki M, Frytak S, Parkinson DR: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993:11:1269-1275.
6. Santoro A, Tursz T, Mouridsen H, Verweig J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E, Kirkpatrick A, van Glabbeke M, van Oosterom A: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcoma. A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995:13:1537-1545.
7. Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors: Biology and clinical applications. N Engl J Med 1989:321:1449-1459.
8. World Health Organisation: WHO Handbook for reporting results of cancer treatment. WHO offset publication No. 48. Geneva. Switzerland. WHO. 1979.
9. Mansi JL, Fisher C, Wiltshaw E, Macmillan S, Knig M, Stuart-Harris R: A phase I-II study of ifosfamide in combination with adriamycin in the treatment of adult soft tissue sarcoma. Eur J Cancer Clin Oncol 1988:24:1439-1443.
10. Elias A, Ryan L, Sulkes A, Collins J, Aisner J, Antman KH: Response to mesna. doxorubicin, ifosfamide and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol 1989;7:1208-1216.
11. Antman K, Crowley J, Balccrzak SP, Rivkin SE, Weiss GR, Elias A, Natale RB, Cooper RM, Barlogie B, Truinp DL, Doroshow JH, Aisner J, Pugh RP, Weiss RB, Cooper BA, Clamond GH, Baker LH: An intcrgroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mcsna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993:11:1276-1285.
12. Weh HJ, Zornig C, Hoffknecht MH, Schwarz R, Hossfeld DK: Metastasectomy following chemotherapy in patients with advanced soft tissue sarcomas. On kologic 1992:15:470-474.